T1	Participants 64 84	postmenopausal women
T2	Participants 182 194	osteoporosis
T3	Participants 300 314	gastric ulcers
T4	Participants 428 497	healthy postmenopausal women stratified by Helicobacter pylori status
T5	Participants 507 619	Subjects were randomized to receive risedronate 5 mg (n = 318) or alendronate 10 mg (n = 317) daily for 14 days.
T6	Participants 1916 1930	gastric ulcers
T7	Participants 2003 2040	bisphosphonate related gastric ulcers
